Trial · NCT04605588
A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19
NCT04605588, Phase 2, Terminated, Rutgers, The State University of New Jersey; results first posted 2022-05-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19. Trials, record NCT04605588. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04605588
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19
- NCT number
- NCT04605588
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- Rutgers, The State University of New Jersey
- Conditions
- SARS-CoV Infection, Covid19
- Interventions
- Nitazoxanide, Placebo Nitazoxanide, Ribavirin, Placebo Ribavirin, Hydroxychloroquine, Placebo Hydroxychloroquine
- First posted
- 2020-10-28
- Last updated
- 2022-05-05
- Results first posted
- 2022-05-05
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of Decline in Viral Load Over the 10 Days After Randomization | 10 days after randomization | qPCR measured via nasal swab |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Rate of Decline in Viral Load Over the 10 Days After Randomization | 10 days after randomization | This trial was terminated due to lack of enrollment. A total of 7 participants were randomized. Study outcome was to be response to antiviral treatment (rate of decline in viral load over the 10 days after randomization) as measured via nasal swab qPCR analysis. Based on the lack of enrollment, the swab analysis was not performed. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Active Study Drug | 2 | |
| Overall Study | STARTED | Placebo | 5 | |
| Overall Study | COMPLETED | Active Study Drug | 1 | |
| Overall Study | COMPLETED | Placebo | 5 | |
| Overall Study | NOT COMPLETED | Active Study Drug | 1 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Active Study Drug | 0 | 1 |
| Total, all-cause mortality | Placebo | 0 | 5 |
| Total, other adverse events | Active Study Drug | 0 | 1 |
| Total, other adverse events | Placebo | 0 | 5 |
| Total, serious adverse events | Active Study Drug | 0 | 1 |
| Total, serious adverse events | Placebo | 0 | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Active Study Drug vs Placebo: deaths from any cause | Trial comparisons |
| Active Study Drug vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04605588
GET https://conductscience.org/api/trials/v1/NCT04605588/registered